Background: Metformin (MF), a diabetic drug, has antineoplastic activity as adjuvant therapy for breast cancer and prostate cancer. MF is thought to work via inhibition of mammalian target of rapamycin and activation of p53 and liver kinase B1 via adenosine 5 0 -monophosphate-activated protein kinase. We investigated survival, recurrences and metastasis in patients with type 2 diabetes mellitus (DM2) along with colorectal cancer (CC) or lung cancer (LC) taking MF using the electronic medical record in Memphis Veterans Affairs Medical Center (colon, n ¼ 202; lung, n ¼ 180).
INTRODUCTION

B
efore the turn of the 20th century, a diagnosis of type 2 diabetes mellitus (DM2) was synonymous with insidious death. Defronzo 1 described the Ominous Octet, noting that insulin resistance at the levels of skeletal muscle and liver only denotes a part of the diabetes story and that interactions at other end organs also play a leading role. Recently, associations between DM2 and increased risk of cancer have been established, with cancer being recognized as a potential complication of DM2. 2 Jamal et al 3 noted a 3-fold increase in the risk of pancreatic cancer and a 2-fold increase in the risk of extrahepatic biliary cancer in diabetic American veterans compared with nondiabetic veterans. A 1.3-fold increase in the risk of colon cancer in patients with DM2 versus patients without diabetes was recently noted by Peeters et al, 4 corroborating the results of several prior studies, which also noted a modest increase in colorectal cancer (CC) risk in patients with DM2. Several different studies investigated the relationship between hyperglycemia and cancer risk, however, it was noted that improvement in and optimization of glycemic control did not necessarily lead to a decrease in risk or prevalence of malignancy. 2, [5] [6] [7] [8] Evidence identifying the relationship between insulin resistance with hyperinsulinemia and malignancy is rapidly evolving. The Cremona study from Italy was a population study evaluating the prevalence of DM as well as insulin resistance or hyperinsulinemia and cancer mortality over a total of 15 years. At the 15-year mark, there were 180 cancer-related deaths out of 2,011 white patients. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and smoking were independently noted to be associated with cancer mortality. It was also noted that patients with insulin levels in the highest quintile had a 62% higher risk of cancer mortality and a 161% higher risk of gastrointestinal cancer mortality. 9 We have studied prostate cancer with apparent comparable improvement in cancer outcomes. 10 Other recent literature also contains a few studies, most supporting improved outcomes with metformin (MF) use in a number of different cancers, including nonsmall cell lung cancer (NSCLC) 11 and CC 12 Both these studies address associated improved survival of patients with cancer taking MF and propose that MF should be used as adjuvant therapy. In this article, we observed survival rates in addition to recurrence rates and metastatic disease in patients.
There are many biochemical mechanisms that could link DM2 and malignancy. Data from in vitro and in vivo studies suggest interactions between hyperinsulinemia, insulin receptors and insulin-like growth factor (IGF)-1/2 receptors in endocrine, autocrine and paracrine functions as possible etiologies. The insulin receptor, IGF-1R and IGF-2R are tyrosine kinase receptors with significant homology. Binding through any of these receptors would lead to the activation of mitogen activated protein kinase (MAPK), phosphotidyl inositol 3 kinase (PI3K) and Janus kinase signaling. 13 Signaling through PI3K/Akt and Ras/MAPK pathways upregulates the mammalian target of rapamycin (mTOR) activity, ultimately leading to increased cell proliferation, protein synthesis and reduction of apoptosis. Aberrant mTOR signaling is thought to be present in up to 80% of human malignancies.
14 Adenosine 5 0 -monophosphateactivated protein kinase (AMPK) is a serine/threonine kinase that senses and regulates mTOR activity, and as such, is integral to cell metabolism, cell growth and autophagy. Tumor cells are known to have established mechanisms to dampen AMPK signaling, leading to uninhibited cell proliferation. 15 Interestingly, inactivation of a gene for tumor suppressor and serine/threonine kinase, liver kinase B1 (LKB1), which is found upstream of AMPK and is required for its activation, was found to be responsible for genetic susceptibility to Peutz-Jeghers syndrome. LKB1 is also noted to be the second most commonly mutated tumor suppressor in sporadic human lung cancer and is present in at least 15-30% of NSCLCs.
16
LKB1 phosphorylates AMPK leading to an increase in the adenosine monophosphate/adenosine triphosphate (AMP/ATP) ratio, thus regulating cell polarity, cell growth and cell autophagy through the inhibition of mTOR. 15, 16 Metformin, a first-line antihyperglycemic medication, is thought to have both direct and indirect antitumor effects. In a review article, Duque et al 17 notes that MF downregulates oxidative stress and alters the ATP/AMP ratio leading to indirect activation of AMPK. MF may also stimulate the tumor suppressor LKB1, which would cause direct activation of AMPK and inhibition of mTOR. This theory has been tested in patients with and without diabetes, revealing varying results.
The well-established inhibitory effect of MF on complex 1 of the electron transport chain, which is required for tumorigenicity, is a major contributor to MF's overall anticancer effect. Inhibition of complex 1 causes energetic stress within the cells and increases the AMP/ATP ratio, and the increase in AMP directly causes hepatic AMPK activation, leading to a decrease in gluconeogenesis. 18 Our group conducted a retrospective analysis of Veteran patients with DM2 and prostate cancer who were treated for their DM2 with regimens including and not including MF. We found that patients with DM2 and prostate cancer had significant improved survival, decline in secondary cancers and metastasis. PSA levels were also reduced in the patients treated with MF. 10 NSCLC consists of 85% of all lung cancers and still has 5-year survival rates of 15-18%. Colon cancer survival rates have been improving over the past 60 years, and screening has led to a decrease in the incidence of CC. However, colon cancer still ranks as the third highest cause of cancer death in both men and women. As the Memphis Veteran Affairs Medical Center (MVAMC) has high rates of colon cancer and lung cancer, we chose to investigate the association of MF in patients diagnosed with NSCLC or colon cancer with DM2, on MF therapy or without MF therapy. In this study, we hypothesized that MF therapy would be associated with improved overall survival, reduced metastasis and reduced recurrences in patients with DM2 and either CC or NSCLC.
The primary end point for both studies was overall survival. Secondary end points included recurrences, metastases and secondary malignancies.
METHODS
The MVAMC Institutional Review Board approved this study design. The Tumor Registry at MVAMC provided a separate cohort of patients with CC and a separate cohort of patients with NSCLC, each diagnosis identified by ICD-9 codes between 1998 and 2012. A retrospective chart review was conducted using the electronic medical record. Inclusion criteria included patients who were diagnosed with DM2 before a diagnosis of either CC or NSCLC. Patients were included in the MF group if they had a history of DM2 and had been treated with MF for 2 years or greater. Patients treated with any other hypoglycemic agent except MF were included in the non-MF (NMF) group.
For the first arm of the project, a total of 202 patients with CC were extracted from the cohort. The MF group contained 104 patients and the NMF group contained 98 patients. Patients were matched for age and race. The patients were observed for carcinoembryonic antigen levels, recurrences, metastases, secondary malignancies and survival.
The second arm of the study included 180 patients with NSCLC, 93 patients in the MF group and 87 patients in the NMF group. Patients were matched for age, race and smoking status and were observed for recurrences, metastases, secondary malignancies and survival ( Figure) .
Data for both arms of the study were analyzed using independent samples t test and chi-squared test. Analysis of covariance and logistic regression were performed to test for significant results while controlling for potential confounders. Cohen's d and Cramer's V effect sizes were also calculated.
RESULTS
Colon
Most baseline characteristics were matched (Table 1) . However, a significant difference was noted regarding body mass index (BMI), hemoglobin A1c, creatinine and age at diagnosis. MF group patients with DM2 and CC were found to have a higher mean BMI than NMF group patients (29.8 versus 26.0, P o 0.001) as well as a higher hemoglobin A1c than NMF group patients (7.4 versus 6.7%, P ¼ 0.002). Patients in the NMF group were found to have a higher creatinine at baseline (2.3 versus 1.5 mg/dL, P ¼ 0.010) and were older when diagnosed with cancer (67.4 versus 64.9 years, P ¼ 0.049) than the patients in the MF group.
As shown in Table 2 , outcomes were significant for more MF group patients living (51.9% versus 24.5%, P o 0.001) than NMF group patients and for more patients having a carcinoembryonic antigen decrease (72.1% versus 46.7%, P ¼ 0.015), improved 5-year survival (56.3% versus 33.7%, P ¼ 0.001), improved overall survival (5.7 versus 4.1 years, P ¼ 0.007), decreased metastasis in the MF versus NMF group (23.1% versus 45.9%, P ¼ 0.001) and decreased recurrences (4.3% versus 18.8%, P ¼ 0.003). None of these outcomes changed when controlling for any of the significant baseline differences.
Non-Small Cell Lung Cancer
Significant differences in the baseline characteristics (Table 3 ) in this cohort included higher hemoglobin A1c in the MF group versus NMF group (7.6 versus 7.1%, P ¼ 0.043) and more whites and fewer African Americans (65.6% versus 50.6%, 32.3% versus 49.4%, P ¼ 0.024). NMF group patients compared with MF group patients had higher creatinine levels (1.1 versus 1.4 mg/dL, P ¼ 0.029) and were older at the time of cancer diagnosis (69.4 versus 66.6 years, P ¼ 0.035). Tables 3 and 4 show that overall survival and 5-year survival were significantly greater in the MF versus NMF (3.4 versus 1.8 years, P o 0.001), (29.0% versus 14.9%, P = 0.023). The MF group also experienced a longer period of progression-free remission than the NMF group (2.3 versus 1.1 years, P = 0.008). Controlling for age at diagnosis resulted in 5-year survival becoming nonsignificant (P = 0.061). No other baseline differences significantly affected outcome findings.
Outcomes in
DISCUSSION
Overall, the results of both the CC and the NSCLC studies suggest that treatment modalities that include treatment with MF therapy are associated with improvement in overall survival in patients with CC and NSCLC along with DM2. In patients with CC, secondary parameters showed significant improvement in the MF group versus NMF group. Except in one instance, findings were unchanged when controlling for significant baseline differences.
Though patients were matched, it was noted that patients with CC in the MF group were significantly more overweight, though both the MF and NMF groups had BMI levels greater than 25. There was no significant difference in BMI in the NSCLC cohort. Calle et al 19 found in a prospective study that mortality from colon cancer increased as the BMI increased above the reference range of weight (18.5-24.9) . Patients with BMIs in the range of 25-29.9 were found to have a 1.2 mean relative risk of death secondary to colon cancer. This same study found that an elevated BMI was protective in male patients with lung cancer. 19 Interestingly, MF has also been hypothesized as having a role against cancer cachexia. It is theorized that MF may activate hypothalamic AMPK pathway that could alter neuropeptide signaling in the hypothalamus and protect against cancer cachexia.
17 Our study was not designed to investigate this topic and further prospective trials would be needed; however, this could be a possible explanation for the elevated BMI in our CC MF group.
Glycemic control was less well achieved in the MF group versus the NMF group in both CC and NSCLC. This baseline characteristic is important. It suggests that glycemic control is not the etiology of the improved survival and secondary outcomes associated with MF therapy in our study and that both direct and indirect antitumor effects of MF are involved.
Our study is subject to selection bias as is evident in the lower creatinine levels in the MF versus NMF group in both CC and NSCLC. Recently, the Food and Drug Administration revised the recommendation for MF therapy in patients with renal disease from being based on creatinine to estimated glomerular filtration rate. However, previously the Food and Drug Administration recommended cessation of MF therapy with a creatinine of 1.4 mg/dL in women and 1.5 mg/dL in men.
Although MF therapy is associated with a significant improvement in primary outcomes in both CC and NSCLC, this improvement in secondary parameters was not noted in patients with DM2 and NSCLC. Reasons for the differences in secondary outcomes cannot be inferred from our study. However, we speculate that differences in the mechanism of development of these 2 different categories of cancer may affect response to MF therapy. It has been noted that NSCLC in mouse models with mutations in LKB1 and KRAS, but not LKB1 and p53 mutations, prolonged survival thought to be secondary to a selective response to phenformin, an earlier biguanide analogue of the current most commonly used antihyperglycemic biguanide medication MF. It is possible that the presence of multiple mutations in various forms of NSCLC led to the development of tumor cells that are no longer responsive to MF.
Limitations of our study includes selection bias, length time bias and differences in the therapies among the 2 treatment groups, as well as the limitations in generalizability due to a predominantly male, Veteran population.
A number of investigators have studied CC and MF, most demonstrating an improvement in many outcome parameters such as MF being associated with reduced incidence of cancer-related deaths 20 as we have demonstrated. Some investigators have also shown lesspositive outcomes that do not demonstrate a significant difference in the outcome of patients with CC who use MF versus those who do not. 21 In conclusion, our study notes that MF therapy is associated with marked improvements in primary and secondary outcomes in CC or NSCLC and DM2. Prospective trials are needed to confirm and fully establish the therapeutic benefits of MF therapy in CC and NSCLC. 
